-
Something wrong with this record ?
Renal cell carcinoma with intracardiac tumor thrombus extension: Radical surgery yields 2 years of postoperative survival in a single-center study over a period of 30 years
P. Zacek, M. Brodak, J. Gofus, J. Dominik, P. Moravek, M. Louda, M. Podhola, J. Vojacek
Status not-indexed Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
- Publication type
- Journal Article MeSH
BACKGROUND: Renal cell carcinoma (RCC) with tumor thrombus extension into the right atrium (level IV) is a rare life-threatening clinical condition that can only be managed by means of a combined urological and cardiac surgical approach. The early and late outcomes of this radical treatment were analyzed in a large single-institution series over a period of 30 years. METHODS: In 37 patients with RCC and intracardiac tumor thrombus extension, nephrectomy was performed followed by the extraction of the intracaval and intracardiac tumor thrombus under direct visual control during deep hypothermic circulatory arrest (DHCA). Recently, in 13 patients, selective aortic arch perfusion (SAAP) was instituted during DHCA. RESULTS: In all patients, precise removal of the tumor thrombus was accomplished in a bloodless field. The mean duration of isolated DHCA was 15 ± 6 min, and 31.5 ± 10.2 min in the case of DHCA + SAAP, at a mean hypothermia of 22.7 ± 4°C. In-hospital mortality was 7.9% (3 patients). In Kaplan-Meier analysis, the estimated median survival was 26.4 months whereas the 5-year cancer-related survival rate was 51%. CONCLUSIONS: Despite its complexity, this extensive procedure can be performed safely with a generally uneventful postoperative course. The use of cardiopulmonary bypass with DHCA, with the advantage of SAAP, allows for a safe, precise, and complete extirpation of intracaval and intracardiac tumor mass. Late outcomes after radical surgical treatment in patients with RCC and tumor thrombus reaching up in the right atrium in our series justify this extensive procedure.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23003028
- 003
- CZ-PrNML
- 005
- 20230421100003.0
- 007
- ta
- 008
- 230413s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fonc.2023.1137804 $2 doi
- 035 __
- $a (PubMed)36816971
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Zacek, Pavel $u Department of Cardiac Surgery, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec, Kralove, Czechia
- 245 10
- $a Renal cell carcinoma with intracardiac tumor thrombus extension: Radical surgery yields 2 years of postoperative survival in a single-center study over a period of 30 years / $c P. Zacek, M. Brodak, J. Gofus, J. Dominik, P. Moravek, M. Louda, M. Podhola, J. Vojacek
- 520 9_
- $a BACKGROUND: Renal cell carcinoma (RCC) with tumor thrombus extension into the right atrium (level IV) is a rare life-threatening clinical condition that can only be managed by means of a combined urological and cardiac surgical approach. The early and late outcomes of this radical treatment were analyzed in a large single-institution series over a period of 30 years. METHODS: In 37 patients with RCC and intracardiac tumor thrombus extension, nephrectomy was performed followed by the extraction of the intracaval and intracardiac tumor thrombus under direct visual control during deep hypothermic circulatory arrest (DHCA). Recently, in 13 patients, selective aortic arch perfusion (SAAP) was instituted during DHCA. RESULTS: In all patients, precise removal of the tumor thrombus was accomplished in a bloodless field. The mean duration of isolated DHCA was 15 ± 6 min, and 31.5 ± 10.2 min in the case of DHCA + SAAP, at a mean hypothermia of 22.7 ± 4°C. In-hospital mortality was 7.9% (3 patients). In Kaplan-Meier analysis, the estimated median survival was 26.4 months whereas the 5-year cancer-related survival rate was 51%. CONCLUSIONS: Despite its complexity, this extensive procedure can be performed safely with a generally uneventful postoperative course. The use of cardiopulmonary bypass with DHCA, with the advantage of SAAP, allows for a safe, precise, and complete extirpation of intracaval and intracardiac tumor mass. Late outcomes after radical surgical treatment in patients with RCC and tumor thrombus reaching up in the right atrium in our series justify this extensive procedure.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Brodak, Milos $u Department of Urology, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec, Kralove, Czechia
- 700 1_
- $a Gofus, Jan $u Department of Cardiac Surgery, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec, Kralove, Czechia
- 700 1_
- $a Dominik, Jan $u Department of Cardiac Surgery, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec, Kralove, Czechia
- 700 1_
- $a Moravek, Petr $u Department of Urology, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec, Kralove, Czechia
- 700 1_
- $a Louda, Miroslav $u Department of Urology, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec, Kralove, Czechia
- 700 1_
- $a Podhola, Miroslav $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec, Kralove, Czechia
- 700 1_
- $a Vojacek, Jan $u Department of Cardiac Surgery, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec, Kralove, Czechia
- 773 0_
- $w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 13, č. - (2023), s. 1137804
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36816971 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230413 $b ABA008
- 991 __
- $a 20230421095956 $b ABA008
- 999 __
- $a ok $b bmc $g 1922751 $s 1189235
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 13 $c - $d 1137804 $e 20230201 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
- LZP __
- $a Pubmed-20230413
